Views: 280 Author: Rchemsell Publish Time: 2026-09-19 Origin: Site
Content Menu
● China's Peptide Manufacturing Advantage
● Top 10 Cagrilintide Manufacturers in China
>> 1. Rchemsell
>> 2. Sinopep-Allsino Biopharmaceutical
>> 5. Zhejiang Peptides Biotech
>> 6. Enogen
>> 9. KiloBio
● Technical Procurement Notes for Cagrilintide Projects
>> Key Technical Factors to Specify
>> Avoid Irrelevant Certifications
● The Hidden Procurement Trap: "Purity Is Not Content"
● Buyer's Guide: How to Verify a Cagrilintide Supplier
>> Step 1: Start With a Controlled RFQ
>> Step 2: Verify the Legal Entity
>> Step 3: Check Certificates Properly
>> Step 4: Buy a Representative Sample
>> Step 5: Control Logistics Risk
● FAQ
>> 1. Is Cagrilintide approved for commercial use in the United States or European Union?
>> 2. How can I confirm that a supplier's ISO certificate has not expired?
>> 3. Does a 99% HPLC result mean I am buying 99% active peptide?
>> 4. What minimum documents should I request before ordering a Cagrilintide-related sample?
>> 5. Can a research-peptide supplier provide material for human injection or clinical use?
China has become an important global sourcing base for peptide development, custom synthesis, analytical services, and scalable peptide manufacturing. However, a buyer searching for a Cagrilintide manufacturer in China must distinguish carefully between research-use peptide suppliers, custom-synthesis providers, cosmetic-ingredient companies, and regulated pharmaceutical CDMOs.
Cagrilintide is a long-acting amylin analogue under clinical development by Novo Nordisk. It is not a generic commodity that a purchaser should treat as a routine consumer-product ingredient or assume is approved for human use in every market. The practical procurement opportunity in China is therefore most often centered on research-use material, analytical reference work, custom peptide development, process-development services, and qualified pharmaceutical CDMO discussions—all subject to intellectual-property, regulatory, import/export, and intended-use requirements.
For international buyers, the correct supplier is not necessarily the largest supplier. It is the company whose quality system, analytical package, scale, documentation, confidentiality process, and commercial terms fit the actual project stage.
This list is designed for procurement managers, biotech sourcing teams, laboratory buyers, and cosmetic-sector developers who need a transparent framework—not a generic list of names.
We assessed companies using publicly available information and practical B2B procurement criteria:
| Evaluation Criterion | What Buyers Should Verify | Why It Matters |
|---|---|---|
| Manufacturing focus | Research-grade synthesis, GMP peptide API, custom synthesis, CDMO, or cosmetic peptide capability | A research supplier is not automatically qualified for regulated clinical or commercial API supply |
| Analytical capability | HPLC, LC-MS, impurity analysis, method development, stability support, batch COA | Purity alone does not prove molecular identity, impurity control, or lot-to-lot repeatability |
| Scale flexibility | Milligram, gram, kilogram, or commercial-scale production | Buyers need a realistic route from feasibility work to larger supply |
| Quality-system evidence | GMP status, audit history, inspection evidence, ISO certification, data integrity practices | Certificates must be current, scope-specific, and independently verifiable |
| Documentation | COA, chromatograms, MS data, traceability, change control, SDS, quality agreement | Documentation controls downstream laboratory, regulatory, and logistics risk |
| OEM/ODM support | Packaging, labeling, lyophilization, private-label coordination, formulation support | Relevant primarily for permitted research, cosmetic, or non-drug projects—not a substitute for drug approval |
| Communication and responsiveness | Technical response quality, quotation clarity, sample timeline, deviation handling | Poor communication can delay qualification more than the synthesis itself |
| Export readiness | Temperature-sensitive packaging, customs documentation, transport planning | Peptide stability and import rules can affect the delivered material |
Important compliance clarification: Cagrilintide has been described by Novo Nordisk as an investigational long-acting amylin analogue. Its combination product CagriSema has been in clinical development, and legal approval, patent rights, and permitted use vary by jurisdiction. Buyers should obtain legal and regulatory advice before procuring, importing, developing, marketing, or using any material associated with a patented or investigational drug substance.
China's peptide industry does not operate from one single manufacturing cluster. Instead, it combines several regional strengths:
- Shanghai is a major center for pharmaceutical R&D, life-science distribution, custom peptide work, and international-facing biotech services.
- Hangzhou and Zhejiang support peptide CDMO development, process scale-up, commercial API manufacturing, and access to advanced pharmaceutical supply chains.
- Jiangsu has established strengths in pharmaceutical manufacturing infrastructure, quality systems, and API-oriented production.
- Shenzhen and Guangdong contribute biotechnology talent, research services, diagnostic innovation, and export-oriented commercial operations.
- Xi'an and Shaanxi have developed chemical, botanical-extract, and life-science supply networks, although supplier qualification standards vary substantially between companies.
The strategic advantage is not simply lower price. It is the ability to match a project with the appropriate combination of solid-phase peptide synthesis capability, purification capacity, analytical testing, lyophilization, packaging, documentation, and export logistics.
For Cagrilintide-related inquiries, buyers should be especially cautious about unsupported claims such as "pharmaceutical grade," "GMP grade," "FDA approved," or "clinical ready." These descriptions require documentary evidence that matches the product, facility, country, batch, and intended use.
The following companies are listed as potential peptide-manufacturing, custom-synthesis, research, or CDMO partners based on their publicly described peptide capabilities. Inclusion is not an endorsement, regulatory approval, legal clearance, or confirmation that a company is authorized to manufacture, sell, or commercialize Cagrilintide for any specific use.
Best fit for: Research laboratories, early-stage product teams, small and medium-sized brands, distributors, and buyers requiring flexible custom peptide supply and coordinated service.
Rchemsell is positioned as a China-based peptide R&D and manufacturing partner serving laboratory research and cosmetic-industry customers. Its core service model combines peptide synthesis, quality testing, lyophilization, packaging, and shipping coordination. For projects requiring non-standard specifications, Rchemsell also supports custom peptide synthesis, OEM, and ODM-oriented collaboration.
For B2B buyers, Rchemsell's practical advantage is flexibility. Large pharmaceutical CDMOs are often optimized for major development programs, high documentation burdens, and large-scale commitments. Smaller buyers may instead need faster technical communication, manageable minimum quantities, customized packaging, staged sampling, or support for specific sequences and purity targets.
Rchemsell states that its peptide products can reach 98%–99% purity, subject to the agreed specification and analytical criteria. Buyers should still request batch-specific evidence, including HPLC purity documentation, LC-MS identity confirmation where appropriate, lot traceability, storage instructions, and packaging details.
Core strengths:
- Flexible custom peptide synthesis for research and commercial-development projects
- Integrated testing, freeze-drying, packaging, and shipment support
- Suitable for buyers needing a responsive supplier for smaller or customized orders
- OEM and ODM support for permitted cosmetic and branded-development projects
- Potentially lower coordination burden for buyers who prefer one supplier across synthesis, testing, and packaging
Recommended buyer question:
"Can you provide a batch-specific COA, HPLC chromatogram, LC-MS result, salt-form information, storage recommendation, and a written change-notification process before sample approval?"
Public contact page:
Best fit for: Biopharma companies needing a structured peptide or oligonucleotide CDMO partner for CMC development and regulated-scale manufacturing discussions.
Sinopep-Allsino Biopharmaceutical is headquartered in Hangzhou and was founded in 2009, according to public company-profile information. The company is described as working with peptide, oligonucleotide, and small-molecule drug development and manufacturing.
Its public materials position the company as a full-service peptide and oligonucleotide CDMO supporting end-to-end CMC development and commercial GMP manufacturing. This profile makes it more relevant to buyers with regulated-development needs than to purchasers simply seeking low-cost research vials.
Core strengths:
- Peptide and oligonucleotide CDMO positioning
- CMC development and scale-up orientation
- Commercial manufacturing focus for global biopharma partners
- Potential fit for projects requiring formal quality and development infrastructure
Main market focus: Global pharmaceutical and biotechnology companies.
OEM/ODM relevance: More appropriate for regulated development and contract manufacturing than consumer-style OEM or private-label programs.
Buyer caution: Confirm whether the exact project can be accepted at its current stage, whether the requested peptide is legally eligible for the intended work, and whether the company's GMP scope covers the requested site, process, and dosage-form requirements.
Best fit for: Buyers requiring custom GMP peptide development, clinical-stage supply discussions, and scale flexibility from discovery through larger batch production.
CSBio China states that it has produced custom-manufactured peptides since 1993 and operates facilities designed for GMP peptide production. Its public materials report experience supplying clinical-grade peptides for toxicology studies and Phase I, II, and III clinical trials.
The company describes custom peptide capability ranging from milligrams to kilograms, including linear and complex peptides with modifications. It also reports support for purity requirements from crude material to 98% and above, depending on customer application requirements.
Core strengths:
- Long-established custom peptide manufacturing experience
- GMP-oriented peptide production positioning
- Range from research quantities to kilogram-scale output
- Technical consultation for sequence design and custom manufacturing
- Potential fit for complex modified peptides and clinical-development workflows
Main market focus: Pharmaceutical research, new-drug R&D, clinical development, and specialty peptide manufacturing.
OEM/ODM relevance: Limited for typical consumer OEM. Stronger fit for custom manufacturing and CRDMO collaboration.
Buyer caution: Request current inspection and facility evidence directly. A company-wide GMP claim should never replace verification of the actual production line, quality-system scope, and proposed batch record requirements.
Best fit for: Research institutions, biotech companies, reagent buyers, and development teams requiring a broad catalog combined with custom peptide and antibody services.
GL Biochem is a Shanghai-based life-science company recognized for peptide reagents, custom peptides, custom antibodies, and pharmaceutical peptide-related services. According to its public profile, the company has a 100,000-square-meter headquarters in Shanghai, five global manufacturing sites, two R&D centers, and more than 1,000 employees.
For procurement teams, GL Biochem can be a logical option when the project combines catalog reagents, custom sequences, peptide modifications, antibodies, and research-scale supply. Its broad service menu is particularly useful for buyers who want to consolidate multiple research procurement categories.
Core strengths:
- Broad peptide-reagent and custom-synthesis portfolio
- International operational footprint
- Research-oriented supply combined with pharmaceutical peptide services
- Relevant for custom sequences, modifications, and research workflows
- Strong fit for academic, diagnostic, and discovery-stage purchasing
Main market focus: Research institutions, biotechnology companies, pharmaceutical R&D teams, and international life-science buyers.
OEM/ODM relevance: More appropriate for research and custom-synthesis supply than typical cosmetic OEM/ODM programs.
Buyer caution: Ask the supplier to distinguish clearly between research-grade material and GMP or clinical-grade material. Do not assume that catalog availability establishes regulatory suitability.
Best fit for: Buyers seeking a China-based peptide manufacturer with stated capacity across peptide APIs, cosmetic peptides, custom peptide synthesis, CRO, and CMO projects.
Zhejiang Peptides Biotech, often referred to as ZPC, was established in 2014 according to its public company information. It describes offerings that include peptide APIs, custom peptides, cosmetic peptides, amino acids, intermediates, CRO, and CMO services.
The company states that it has a GLP-certified R&D center of about 3,000 square meters and a cGMP manufacturing site. Public descriptions indicate supply capability from milligram-scale research work through multi-kilogram commercial batches.
Core strengths:
- Broad product range across APIs, cosmetic peptides, and custom synthesis
- Custom peptide modification and scale-up capability
- Potential fit for buyers moving from research to commercial production
- Stated focus on cGMP, USP, and EP-aligned manufacturing expectations
- Useful option for buyers evaluating both pharmaceutical and cosmetic peptide supply paths
Main market focus: Pharmaceutical development, peptide API supply, cosmetics, research institutions, and international distributors.
OEM/ODM relevance: Relevant for custom peptide and cosmetic peptide projects; buyers should confirm whether the requested OEM scope includes formulation, filling, packaging, labeling, or only bulk ingredient supply.
Buyer caution: Public claims about certifications, manufacturing capacity, and planned regulatory inspections should be verified directly using valid certificates, applicable license numbers, audit reports, and current facility scope.
Best fit for: Pharmaceutical and biotechnology teams seeking GMP-oriented peptide API manufacturing, analytical development, and regulatory-support services.
Enogen is a China-based peptide API manufacturer and CDMO that states it has operated since 2015. Its public materials describe services including GMP-grade peptide APIs, custom synthesis, non-GMP custom synthesis, analytical development, and regulatory support.
This makes Enogen a relevant candidate for buyers who require more than basic synthesis. Its service scope suggests potential value in projects where analytical method development, process development, and regulatory documentation are part of the purchasing decision.
Core strengths:
- GMP-grade peptide API and CDMO positioning
- Custom synthesis for pharmaceutical and biotech customers
- Analytical development and regulatory-support services
- Potential fit for development programs requiring technical transfer planning
Main market focus: Global pharmaceutical and biotechnology organizations.
OEM/ODM relevance: Better classified as pharmaceutical CDMO support rather than consumer-product OEM or ODM.
Buyer caution: Clarify the precise regulatory pathway. "GMP-grade" should be matched to the applicable jurisdiction, intended clinical stage, and the buyer's quality agreement—not used as a blanket equivalence statement.
Best fit for: Research organizations and drug-discovery teams requiring peptide design, screening, modification, conjugation, analysis, and custom manufacturing support.
Creative Peptides publicly describes itself as specializing in peptide process development and manufacturing of bioactive peptides. Its stated service range includes peptide screening, design, synthesis, modification, and analysis, along with CDMO-oriented capabilities.
Its value proposition is strongest for buyers who need technical customization rather than only a standard product. This can include labeled peptides, conjugates, modified peptides, screening libraries, and specialized analytical work.
Core strengths:
- Broad technical service offering from design through analysis
- Custom modification and peptide-conjugation capability
- Suitable for research, early discovery, and specialized project requirements
- CDMO positioning for customers needing process-development support
Main market focus: Research laboratories, drug-discovery companies, biotechnology teams, and specialized life-science buyers.
OEM/ODM relevance: Primarily custom research and CDMO support rather than traditional cosmetic or consumer-product ODM.
Buyer caution: Confirm the legal entity and manufacturing location associated with the specific quotation, since global service brands may use multiple operating entities and sites.
Best fit for: Large pharmaceutical and biotechnology companies requiring substantial development, analytical, regulatory, and commercial manufacturing infrastructure.
WuXi TIDES is associated with peptide and oligonucleotide CRDMO capabilities and is frequently identified in industry directories as a major China-based CDMO option for regulated development programs. Public industry-directory information characterizes its platform as having significant peptide manufacturing capacity and a focus on clinical and commercial supply.
For large or complex projects, the major advantage is scale and an established integrated service environment. For smaller buyers, however, this level of infrastructure may come with higher minimum project thresholds, more formal onboarding requirements, and longer commercial qualification processes.
Core strengths:
- Large-scale CRDMO infrastructure
- Peptide and oligonucleotide development capability
- Suitable for regulated clinical and commercial supply discussions
- Stronger fit for established biopharma programs than small exploratory orders
Main market focus: Global pharmaceutical and biotechnology companies with clinical and commercial development programs.
OEM/ODM relevance: Not a typical consumer-product OEM/ODM partner; focused on regulated contract development and manufacturing.
Buyer caution: Buyers should expect detailed technical-transfer requirements, formal quality agreements, and capacity-scheduling processes. This is not necessarily the best fit for small MOQ or rapid research-grade purchasing.
Best fit for: Development-stage buyers seeking custom synthesis and scale-up support for life-science API intermediates, peptides, and oligonucleotides.
KiloBio is the brand of Ningbo Kilo Biotechnology Co., Ltd., a life-science chemistry company based in Ningbo, China. Its public information describes custom synthesis and CDMO services for API intermediates, peptides, and oligonucleotides from discovery through scale-up, with analytical and GMP-aligned support.
This profile may appeal to sourcing teams that want a partner for early-to-mid-stage chemistry development and a potentially more flexible alternative to the largest multinational CDMOs.
Core strengths:
- Custom synthesis and CDMO orientation
- Peptide and oligonucleotide support
- Discovery-to-scale-up service positioning
- Analytical and GMP-aligned support for development projects
Main market focus: Life-science, pharmaceutical-development, and biotechnology customers.
OEM/ODM relevance: More applicable to development and custom synthesis than to standard private-label manufacturing.
Buyer caution: "GMP-aligned" and "cGMP" are not interchangeable terms. Request documents that identify the exact facility quality status, audit history, release process, and scope for the intended material.
Best fit for: Qualified buyers conducting initial market screening for Cagrilintide-related raw-material sourcing and requiring direct supplier communication about claimed GMP systems.
Superpharma Group publicly markets itself as a China factory supplying Cagrilintide API under GMP-compliant systems for pharmaceutical companies and qualified distributors. Its public page describes bulk purchasing and raw-material sourcing support for global buyers.
This company may be relevant as a sourcing lead, but buyers should conduct an especially rigorous qualification process before relying on claims related to API status, GMP compliance, legal supply rights, or clinical suitability.
Core strengths:
- Directly markets Cagrilintide-related supply
- Export-oriented sourcing language
- Focus on pharmaceutical companies and distributors
- May provide a starting point for market comparison and quotation collection
Main market focus: Pharmaceutical companies, distributors, and global bulk buyers.
OEM/ODM relevance: Not clearly established from public information; confirm whether support extends beyond bulk supply.
Buyer caution: This is a category where public marketing claims require unusually close scrutiny. Before purchasing, request a current GMP certificate, issuing authority, facility address, product scope, batch documentation, analytical raw-data policy, IP/legal compliance statement, and independent audit access.
Publicly reported capacity, MOQ, and certification scope are often incomplete or vary by project. The table below therefore uses practical procurement categories rather than unsupported numeric comparisons. Buyers should obtain written, project-specific quotations and evidence.
| Manufacturer | Primary Positioning | Likely Scale Fit | Typical MOQ Approach | Publicly Stated Quality Focus | Best For |
|---|---|---|---|---|---|
| Rchemsell | Custom peptide, research, cosmetic support, OEM/ODM | Research to small and medium commercial projects | Flexible and project-based | 98%–99% purity target, testing, lyophilization, packaging | Buyers needing customization, communication speed, and coordinated supply |
| Sinopep-Allsino | Peptide and oligonucleotide CDMO | Development to commercial scale | Project and development-program based | GMP manufacturing and CMC development | Biopharma CMC and commercial manufacturing |
| CSBio China | Custom GMP peptide CRDMO | Milligram to kilogram scale | Custom quotation | GMP peptide production | Clinical and custom GMP peptide programs |
| GL Biochem | Peptide reagents and custom synthesis | Research to development scale | Catalog and custom quotation | Research and pharmaceutical peptide services | Research labs and custom sequence projects |
| Zhejiang Peptides Biotech | API, custom, cosmetic peptide, CRO/CMO | Research to multi-kilogram projects | Project-based | Stated cGMP, USP, EP-oriented standards | Buyers needing broad peptide capability |
| Enogen | Peptide API manufacturer and CDMO | Development to commercial scale | Project-based | GMP-grade API and analytical development | Pharma and biotech technical-development programs |
| Creative Peptides | Peptide design, synthesis, modification, analysis | Research to development scale | Custom project-based | Process development and CDMO services | Complex modified peptides and discovery support |
| WuXi TIDES | Large-scale peptide and oligonucleotide CRDMO | Clinical to commercial scale | Formal project qualification | Regulated development and commercial supply | Large pharmaceutical programs |
| KiloBio | Custom synthesis and CDMO | Discovery to scale-up | Project-based | Analytical and GMP-aligned support | Mid-stage chemistry and scale-up projects |
| Superpharma Group | Cagrilintide-related raw-material sourcing | Bulk sourcing inquiry | Quote-based | Claimed GMP-compliant system | Initial supplier comparison, subject to deep verification |
Cagrilintide is not a simple short commodity peptide. Procurement teams should understand that peptide quality depends on more than a final "99% HPLC" claim.
A professional RFQ should include:
- Required sequence and modification details
- Intended use: research, analytical development, formulation study, clinical development, or commercial manufacturing
- Required purity threshold and the HPLC method used to measure it
- Identity verification method, typically LC-MS or high-resolution MS where appropriate
- Salt form, counterion specification, and residual reagent limits
- Required water content and peptide-content method
- Impurity-profile expectations
- Residual solvent requirements
- Endotoxin or microbiological requirements where applicable
- Required stability data and storage conditions
- Packaging format, fill weight, labeling, and shipping temperature
- COA format and access to chromatograms or raw-data review
- Change-control and deviation-notification requirements
A common procurement mistake is asking a peptide manufacturer for CE or RoHS certification.
CE marking applies to certain products regulated under EU harmonization legislation, while RoHS restricts hazardous substances in electrical and electronic equipment. Neither is normally the core quality standard for a peptide active substance, research peptide, or cosmetic ingredient.
For peptide sourcing, the more relevant evidence usually includes:
- GMP status where the intended use requires it
- ISO 9001 quality-management certification, if applicable
- Facility licenses and regulatory inspection evidence
- Analytical-method validation or qualification
- COA and lot traceability
- Quality agreements and change-control procedures
- Product-specific safety, stability, and impurity documentation
- ISO 22716-oriented controls when the intended application is cosmetic manufacturing
One of the least discussed issues in peptide sourcing is the difference between chromatographic purity and actual peptide content.
A supplier may report "99% HPLC purity," meaning the principal peak represents 99% of the integrated chromatographic area under defined conditions. This does not automatically mean that 99% of the weighed powder is active peptide. The material can also contain water, counterions, residual solvents, salts, or other non-peptide components.
For a research study, this can distort concentration calculations. For a formulation project, it can affect dosing, solubility, stability, and cost per active unit. For regulated development, it can become a batch-release and specification issue.
Ask the supplier:
1. Is the stated purity based on HPLC area normalization?
2. What is the peptide content on an as-is basis and an anhydrous basis?
3. What is the water content, and how was it measured?
4. What salt or counterion is present?
5. Are residual solvents tested and reported?
6. Can the supplier provide a chromatogram, MS result, and a COA for the actual batch?
7. Is the quantity quoted based on gross powder weight or corrected peptide content?
This single clarification often separates technically serious suppliers from traders relying on generic marketing specifications.
Do not begin with "Please quote 100 g Cagrilintide, 99% purity." That request is too vague and creates opportunities for mismatched quotations.
Instead, provide a controlled request covering intended use, required analytical documents, quantity, packaging, delivery destination, legal status, quality expectations, and confidentiality requirements.
Before discussing samples, confirm:
- Legal company name in Chinese and English
- Factory address, not only a sales-office address
- Business registration details
- Export capability
- Bank-account name matches the legal entity
- Manufacturing versus trading role
- Named technical and quality contacts
A supplier that cannot clearly identify its factory, quality contact, or legal entity should not progress to a high-value purchase order.
Do not accept a PDF certificate at face value. Verification should include:
- Certificate number
- Issuing organization
- Scope of certification
- Facility address
- Validity dates
- Product and process coverage
- Whether the certificate applies to the manufacturing site or only a related organization
- Independent confirmation with the issuing body where possible
For ISO certificates, check the certification body's accreditation and ask whether the certificate remains valid. For GMP claims, confirm the regulatory authority, inspection date, site address, and scope.
A cheap sample does not automatically qualify a supplier. Your sample plan should test the exact attributes that matter at commercial scale.
Evaluate:
- HPLC purity and peak profile
- LC-MS identity
- Solubility and reconstitution
- Appearance and water content
- Packaging integrity
- Label accuracy
- COA consistency
- Transit stability
- Communication speed when questions arise
If possible, test a second batch. Lot-to-lot comparison provides more meaningful evidence than a single excellent vial.
Peptides can be sensitive to moisture, temperature, oxygen, light, and repeated handling. Ask the supplier to specify:
- Recommended storage temperature
- Whether lyophilization is used
- Primary packaging material
- Desiccant or inert-gas protection
- Cold-chain requirement
- Shipping duration and shipping lane
- Customs paperwork and tariff classification
- Insurance and responsibility for temperature excursions
For global orders, the lowest freight cost is not always the lowest total cost. A delayed shipment with poor packaging can produce more loss than a better-controlled logistics option.
China offers a broad range of peptide suppliers, from flexible custom-synthesis companies to large regulated CDMOs. For a Cagrilintide-related project, the most reliable sourcing strategy is to begin with intended use and evidence requirements—not price per gram.
Rchemsell is a practical option for laboratory research, custom peptide requirements, small and medium-sized development projects, lyophilized packaging, testing coordination, and buyers who value responsive communication and flexible OEM/ODM support. For larger regulated-development programs, companies such as Sinopep-Allsino, CSBio China, Enogen, and WuXi TIDES may be more appropriate candidates for formal CDMO qualification.
Cagrilintide has been under clinical development as a long-acting amylin analogue. Novo Nordisk has described CagriSema, a combination of cagrilintide and semaglutide, as investigational and has stated that it is not approved in the United States or European Union in the cited materials. Buyers must verify the current status in the target market and obtain regulatory and legal advice before any commercial activity.
Ask for the certificate number, certification body, legal entity name, factory address, scope, issue date, and expiry date. Then verify the certificate through the certification body's public directory or by written confirmation. Also confirm that the certified site is the actual manufacturing site for your order, not a sales office or affiliate.
No. HPLC purity typically describes the relative chromatographic peak area under specific conditions. It does not automatically equal peptide content by weight. Ask for peptide-content data, water content, counterion information, residual-solvent results, and the basis on which net content is reported.
At minimum, request a batch-specific COA, HPLC chromatogram, LC-MS identity result, sequence and salt-form description, lot number, net weight, storage conditions, packaging description, SDS where relevant, and a statement of intended-use limitations. For regulated work, request additional quality-system and traceability documentation.
Not automatically. Research-use material, even if it has a high stated purity, is not inherently suitable for human administration, clinical trials, diagnostics, or commercial drug production. Such uses require appropriate legal authorization, GMP compliance, validated specifications, regulatory documentation, and quality agreements specific to the intended use.
1. Novo Nordisk. "[Development of Cagrilintide, a Long-Acting Amylin Analogue]." Describes Cagrilintide as a long-acting amylin analogue in clinical development. [sciencehub.novonordisk]
2. ClinicalTrials.gov. "[Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes]." Clinical-trial record identifying Cagrilintide as an investigational medicine and Novo Nordisk as sponsor. [clinicaltrials]
3. Novo Nordisk. "[Company Announcement on CagriSema Clinical Development]." Describes CagriSema as a fixed-dose combination of Cagrilintide and Semaglutide and outlines related clinical-development programs. [novonordisk]
4. Novo Nordisk. "[NDA Submission Announcement for CagriSema]." Notes that CagriSema was investigational and not approved in the United States or European Union at the time of publication. [prnewswire]
5. Sinopep Biopharma. "[GMP Peptide CDMO and Oligo Manufacturing]." Public company information on peptide and oligonucleotide CDMO, CMC, and commercial manufacturing services. [sinopep]
6. CSBio China. "[GMP Manufactured Peptides]." Public information on GMP peptide production and clinical-grade peptide manufacturing experience. [csbiochina]
7. GL Biochem. "[About GL Biochem]." Public overview of peptide reagents, custom peptide synthesis, antibody services, facilities, and global operations. [glbiochem]
8. Enogen. "[Peptide API Manufacturer in China]." Public overview of GMP-grade peptide API, custom synthesis, analytical development, and regulatory-support services. [enogen.com]
9. KiloBio. "[Custom Synthesis and CDMO Services]." Public description of peptide, oligonucleotide, API-intermediate, analytical, and scale-up services. [kilobio]
10. Zhejiang Peptides Biotech. "[Company Profile]." Public profile describing peptide APIs, cosmetic peptides, custom synthesis, CRO/CMO services, and stated manufacturing capacity. [linkedin]
11. Rchemsell. "[Contact Us]." Company contact page for custom peptide synthesis, quality testing, lyophilization, packaging, and OEM/ODM inquiries.
